Oncology Price Scale Tips Higher: Seattle Genetics Adcetris To Cost Over $100K
This article was originally published in The Pink Sheet Daily
Executive Summary
Amid record-topping oncology drug prices, yet another high-priced therapy will hit the market, following accelerated approval from FDA.
You may also be interested in...
“Emerging Sponsors” Pose Regulatory, Public Relations Challenges For Drug Review Process, FDA’s Jenkins Says
Office of New Drugs director says the agency is seeing more small, inexperienced companies traveling the drug development and approval pathway on their own. However, these firms need more advice from the agency and are all too eager to publicly share their one-sided view about these regulatory interactions.
Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris
FDA approves the antibody-drug conjugate for late stage Hodgkins lymphoma and systemic anaplastic large cell lymphoma Aug. 19.
Disappointing Provenge Sales Stir Doubts About Demand
Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.